Edgewise Therapeutics: Advancing EDG-7500 in Hypertrophic Cardiomyopathy Underpins Buy Rating and Future Value Catalysts

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on EWTX stock, giving a Buy rating on December 24.Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Tessa Romero has given his Buy rating due to a combination of factors tied primarily to the progress of EDG-7500 in hypertrophic cardiomyopathy. The latest updates from the CIRRUS-HCM phase 2 study in both obstructive and non-obstructive patients indicate a favorable emerging profile for EDG-7500 as a potential new cardiovascular therapy. Importantly, the safety data across the 25mg fixed-dose cohorts and the interim 12-week biomarker-guided dosing group show no clinically relevant declines in left ventricular ejection fraction, and atrial fibrillation events have been minimal and not considered drug-related. Management’s confirmation that the affected patient remains on treatment and is doing well further supports confidence in the tolerability of the drug. Looking ahead, Romero views Edgewise Therapeutics’ cardiovascular pipeline, with EDG-7500 at the forefront, as the main driver of equity value. She believes the company is still early in demonstrating the full therapeutic and competitive potential of EDG-7500, with upcoming 12-week Part D data in 2Q26 expected to be a key catalyst for refining the clinical profile and optimizing dosing in both obstructive and non-obstructive HCM populations. The consistency of patient characteristics with prior HCM studies and the successful advancement of most Part D patients to higher dose levels further underpin expectations for meaningful readouts. Taken together, these elements support her constructive outlook on the stock and underpin the Buy recommendation. Romero covers the Healthcare sector, focusing on stocks such as Cytokinetics, Agios Pharma, and Edgewise Therapeutics. According to TipRanks, Romero has an average return of 26.9% and a 57.41% success rate on recommended stocks. In another report released on December 24, Truist Financial also reiterated a Buy rating on the stock with a $46.00 price target.